Evidence map›Paper›PMID 32580945›Full record

ArticleThe Journal of biological chemistry2020

Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLR4 and protect against diabetic nephropathy.

Yurui Duan, Qingyang Luo, Yun Wang, Yali Ma, Fang Chen, Xiaoguang Zhu, Jun Shi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 4 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Integrative Approaches to Treating Cellular Senescence in Kidney Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Biology · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Advancements in diabetes research and stem cell therapy: a concise review.Journal of diabetes and metabolic disorders · 2025
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yurui DuanDepartment of Nephrology, Huaihe Hospital, Henan University, Kaifeng, P. R. China.
Qingyang LuoDepartment of Nephrology, Huaihe Hospital, Henan University, Kaifeng, P. R. China.
Yun WangDepartment of Nephrology, Huaihe Hospital, Henan University, Kaifeng, P. R. China.
Yali MaDepartment of Nephrology, Huaihe Hospital, Henan University, Kaifeng, P. R. China.
Fang ChenDepartment of Nephrology, Huaihe Hospital, Henan University, Kaifeng, P. R. China.
Xiaoguang ZhuDepartment of Nephrology, Huaihe Hospital, Henan University, Kaifeng, P. R. China.
Jun ShiDepartment of Nephrology, Huaihe Hospital, Henan University, Kaifeng, P. R. China. Electronic address: Drshi_jun09@yeah.net.
Henan University Huaihe Hospital and Huaihe Clinical Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic nephropathy (DN) is a complication of diabetes that is increasing in prevalence in China. Extracellular vesicles (EVs) carrying microRNAs (miRs) may represent a useful tool in the development of therapies for DN. Here, we report that EVs released by adipose-derived mesenchymal stem cells (ADSCs) during DN contain a microRNA, miR-26a-5p, that suppresses DN. Using bioinformatic analyses, we identified differentially expressed miRs in EVs from ADSCs and in DN and predicted downstream regulatory target genes. We isolated mesenchymal stem cells (MSCs) from adipose tissues and collected EVs from the ADSCs. We exposed mouse glomerular podocytes and MP5 cells to high glucose (HG), ADSC-derived EVs, miR-26a-5p inhibitor/antagomir, Toll-like receptor 4 (TLR4) plasmids, or the NF-κB pathway activator (phorbol-12-myristate-13-acetate, or PMA). We used the cell counting kit-8 (CCK-8) assay and flow cytometry to investigate the impact of miR-26a-5p on cell viability and apoptosis and validated the results of these assays with

Indexed as

Diabetes Mellitus, ExperimentalDiabetic NephropathiesExtracellular VesiclesAdipose TissueAnimalsMaleMesenchymal Stem CellsMiceMicroRNAsToll-Like Receptor 4MicroRNAsMirn26 microRNA, mouseTlr4 protein, mouseToll-Like Receptor 4adipose-derived mesenchymal stem cellscell biologycell culturecell cyclecell differentiationdiabetesdiabetic nephropathyextracellular vesiclesinflammationmetabolic disorderMicroRNA-328-3pNF-κBToll-like receptor 4 (TLR4)vascular endothelial growth factor

Identifiers

PMID32580945
PMCPMC7489897
OpenAlexW3037898777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.